ClinicalTrials.gg

Myasthenia Gravis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 331 studies for Myasthenia Gravis across more than 10 countries. 145 are recruiting or about to start. 275 of them are mainly about Myasthenia Gravis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Lambert-Eaton Myasthenic Syndrome too: 346 studies, 146 open.

Status

Completed
114
Recruiting
104
Not yet recruiting
34
Active, not recruiting
28
Status unknown
19
Terminated
16

Phase

Phase 3
82
Phase 2
59
Phase 1
34
Early Phase 1
13
Phase 4
10

Where

United States
144
China
88
Italy
68
Canada
59
Germany
58
France
56

Who develops what

Add Myasthenia Gravis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 24 programs from 20 companies, 23 with this as their studies’ main aim; 11 with a live phase 3 study; 12 primary completions in the next 12 months. Compare argenx, AstraZeneca and UCB here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
efgartigimod alfaRecent, limited
Evidence
  • NCT07217587 · Johnson & Johnson · Phase 3 · live · comparator · “Efgartigimod” · registered Oct 2025
argenx100% of its industry studiesUS: argenx (FDA 2021)EU: argenx (EMA 2022)11 study
Immunosuppressive AgentsRecent, limited
Evidence
  • NCT06193889 · Kyverna Therapeutics · Phase 3 · live · background · “Standard lymphodepletion regimen” · registered Oct 2023
—11 study
PrednisoneRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07221838 · AstraZeneca · Phase 4 · live · background · “Prednisone/Prednisolone” · registered Oct 2025
Johnson & Johnson11% of its industry studies11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Decartes-08☆ Track1 live phase-3 study: NCT06799247Cartesian Therapeutics
telitacicept☆ Track1 live phase-3 study: NCT07249632RemeGen Co., Ltd.
efgartigimod alfaApproved: US 2021 · EU 2022☆ Track4 live phase-3 studies: NCT04833894, NCT06392386, NCT06298552argenx
nipocalimabApproved: US 2025 · EU 2025☆ Track3 live phase-3 studies: NCT04951622, NCT05265273, NCT07217587Johnson & Johnson
ravulizumabApproved: US 2018 · EU 2019☆ Track2 live phase-3 studies: NCT07596784, NCT05644561AstraZeneca

The 5 in phase 3 with the nearest primary completion, of 24 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (12)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Dec 2026 est.Decartes-08 · Cartesian Therapeutics · Phase 3 main aimNCT06799247 Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis — primary endpoint: Myasthenia Gravis Activities of Daily Living (MG-ADL) · 128 enrolled
  • 31 Dec 2026 est.telitacicept · RemeGen Co., Ltd. · Phase 3 main aimNCT07249632 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) — primary endpoint: Change from baseline in the MGII (PRO) ocular score · 120 enrolled
  • Mar 2027 est.efgartigimod alfa · argenx · Phase 3 main aimNCT04833894 Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis — primary endpoint: Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL) · 15 enrolled

9 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Myasthenia Gravis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 3

Coming up

56studies finish main data collection within a year17 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger. 16 (15%) take children under 18. 4 (4%) are for women only and 0 (0%) for men only; 13 (13%) take healthy volunteers.

Recruiting studies that take each age, of 104
AgeWomenMen
1013 (13%)11 (11%)
1894 (90%)91 (88%)
3098 (94%)94 (90%)
4098 (94%)94 (90%)
5098 (94%)94 (90%)
6596 (92%)94 (90%)
7588 (85%)86 (83%)
8569 (66%)67 (64%)

Across all 331 studies, recruiting or not: 23% stop at 75 or younger and 11% at 65; 16% take children; 1% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myasthenia Gravis studies take

Of 52 phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 218 mo13–30 · 22 studies——
Phase 330 mo20–43 · 52 studies27 mo19–39 · 43 studies—
Interventional, no phase24 mo11–49 · 35 studies——
Observational52 mo24–… · 62 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 331. Browse all 331 → or search them.